Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Jazz Pharmaceuticals Q2 2024 Adj. EPS $5.30 Beats $4.77 Estimate, Sales $1.024B Beat $1.004B Estimate

Author: Benzinga Newsdesk | July 31, 2024 04:08pm
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $5.30 per share which beat the analyst consensus estimate of $4.77 by 11.11 percent. The company reported quarterly sales of $1.024 billion which beat the analyst consensus estimate of $1.004 billion by 1.95 percent. This is a 6.97 percent increase over sales of $957.317 million the same period last year.

Posted In: JAZZ


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist